LAPTM5 and renal cell carcinoma: To study the expression patterns of LAPTM5 and BMPR1A in clinical samples, we gathered a cohort of 34 RCC metastases from the lung, bone, and brain, as well as 106 normal kidney tissues and 150 primary RCC tissues and performed IHC analysis for both LAPTM5 and BMPR1A.